ÂÜÀòÂÒÂ×

Lily Zou is the Co-founder and CEO of Degron Therapeutics. She is a seasoned executive with comprehensive scientific knowledge in drug discovery and development and extensive business and commercial expertise. Prior to joining Degron, Dr. Zou served as CEO of Fosun Pharma USA, Vice President of Fosun Pharma Group, Healthcare Partner of Fosun Pharma, and Chairman of the Board or Board member of four companies invested by Fosun Pharma. Dr. Zou built and grew Fosun Pharma’s U.S. business and founded Fosun Pharma’s incubator named Fusion Bioventures based in Boston, which invests and incubates early stage innovative biotech companies. Dr. Zou also built a sales and marketing team in the USA for Fosun Pharma drugs and diagnostics, and launched Fosun Pharma’s first products in 2019. Before Fosun, Dr. Zou worked in top management consulting firm (Bain), large pharmas (Novartis/Sandoz, Wyeth, Millennium), and small biotechs (ArQule, Coley).

Dr. Zou received a BS from Beijing University, a PhD in Microbiology and Immunology from Cornell University, and a MBA from MIT Sloan School of Management.